DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on October 29, 2008; DOI: 10.1124/dmd.108.024083


0090-9556/09/3702-424-430$20.00
DMD 37:424-430, 2009

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.024083v1
37/2/424    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ming, X.
Right arrow Articles by Thakker, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ming, X.
Right arrow Articles by Thakker, D. R.

Transport of Dicationic Drugs Pentamidine and Furamidine by Human Organic Cation Transporters

Xin Ming, Wujian Ju, Huali Wu, Richard R. Tidwell, James E. Hall, and Dhiren R. Thakker

Division of Molecular Pharmaceutics (X.M., J.E.H., D.R.T.) and Division of Medicinal Chemistry and Natural Products (W.J.), Eshelman School of Pharmacy, and Department of Pathology, School of Medicine (H.W., R.R.T., J.E.H.), the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

The antiparasitic activity of aromatic diamidine drugs, pentamidine and furamidine, depends on their entry into the pathogenic protozoa via membrane transporters. However, no such diamidine transporter has been identified in mammalian cells. The goal of this study is to investigate whether these dicationic drugs are substrates for human organic cation transporters (hOCTs, solute carrier family 22A1–3) and whether hOCTs play a role in their tissue distribution, elimination, and toxicity. Inhibitory and substrate activities of pentamidine and furamidine were studied in stably transfected Chinese hamster ovary (CHO) cells. The results of [3H]1-methyl-4-phenylpyridinium uptake study showed that pentamidine is a potent inhibitor for all three OCT isoforms (IC50 < 20 µM), whereas furamidine is a potent inhibitor for hOCT1 and hOCT3 (IC50 < 21 µM) but a less potent inhibitor for hOCT2 (IC50 = 189.2 µM). Both diamidines are good substrates for hOCT1 (Km = 36.4 and 6.1 µM, respectively), but neither is a substrate for hOCT2 or hOCT3. The cytotoxicity of pentamidine and furamidine was 4.4- and 9.3-fold greater, respectively, in CHO-hOCT1 cells compared with the mock cells. Ranitidine, an hOCT1 inhibitor, reversed this hOCT1-mediated potentiation of cytotoxicity. This is the first finding that dicationic drugs, such as pentamidine and furamidine, are substrates for hOCT1. In humans, aromatic diamidines are primarily eliminated in the bile but are distributed and cause toxicity in both liver and kidney. These transporters may play important roles in the disposition of aromatic diamidines in humans, as well as resultant drug-drug interactions and toxicity involving diamidine drugs.


Address correspondence to: Dhiren R. Thakker, Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, 3309 Kerr Hall, CB 7360, the University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360. E-mail: dhiren_thakker{at}unc.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics.